Skip to main content
. 2008 Oct 22;10(5):R125. doi: 10.1186/ar2537

Figure 2.

Figure 2

Mean serum levels of vasoendothelial growth factor (VEGF), metalloproteinase-3 (MMP-3), and bone-specific alkaline phosphatase (BALP) in patients with axial spondyloarthritis before and after 12 and 36 to 52 weeks of treatment with adalimumab. *P < 0.05. ns, not significant.